| Record ID | marc_columbia/Columbia-extract-20221130-019.mrc:57944768:1119 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-019.mrc:57944768:1119?format=raw |
LEADER: 01119cam a2200337Ma 4500
001 9170477
005 20120117211256.0
008 110912s2012 ne a b 001 0 eng d
015 $aGBB1B0419$2bnb
016 7 $a015894746$2Uk
020 $a9780444538567 (hbk.)
020 $a0444538569 (hbk.)
035 $a(OCoLC)ocn754168255
035 $a(OCoLC)754168255
035 $a(NNC)9170477
040 $aUKMGB$cUKMGB$dYDXCP$dNNC-M
082 04 $a615.7040724$223
090 $aRA1238$b.G74 2012
100 1 $aGreaves, P.$q(Peter),$cM.B., Ch.B.
245 10 $aHistopathology of preclinical toxicity studies :$binterpretation and relevance in drug safety evaluation /$cPeter Greaves.
250 $a4th ed.
260 $aAmsterdam ;$aOxford :$bAcademic,$c2012.
300 $avi, 886 p. :$bill. (some col.) ;$c25 cm.
504 $aIncludes bibliographical references and index.
650 0 $aDrugs$xToxicity testing.
650 0 $aHistology, Pathological.
650 12 $aDrug Evaluation, Preclinical.
650 22 $aAnimals, Laboratory.
650 22 $aHistology.
650 22 $aPathology.
852 00 $boff,hsl$hRA1238$i.G74 2012